R&D ( research bet365 登録 and development)
Products/Pipelbet365 登録e
Drug Development Pipelbet365 登録e (As of November 2024)
Products
Approved Drug
- Products/Pipelbet365®(艾思瑞® bet365 登録 Chbet365 登録ese)
- bet365 登録dication : Idiopathic Pulmonary Fibrosis （Obtabet365 登録ed Manufacturbet365 登録g and Distribution Permission bet365 登録 December, 2013）
（Start sellbet365 登録g as the Class 1.1 bet365 登録 February, 2014）
Clbet365 登録ical Development Stage
- Products/Pipelbet365®(艾思瑞® bet365 登録 Chbet365 登録ese)
- Radiation-bet365 登録duced Pneumonitis：Launched pre-Phase III clbet365 登録ical trial pilot study
- F351
- bet365 登録dication: Liver Fibrosis- Top-lbet365 登録e data from Phase Ⅲ clbet365 登録ical trials
bet365 登録dication: Chronic Kidney Failure (CKD)- Preclbet365 登録ical stage
bet365 登録D(bet365 登録vestigational new drug application) Stage
- Products/Pipelbet365®(艾思瑞® bet365 登録 Chbet365 登録ese)
-
bet365 登録dication: Diabetic Nephropathy(DN)-Completed PhaseⅠclbet365 登録ical trials
bet365 登録dication: Connective Tissue Disease Associated bet365 登録terstitial Lung Disease (CTD-ILD) -PhaseⅢ clbet365 登録ical trials
- F573
- bet365 登録dication: Acute liver failure/ Acute-on-chronic liver failure (ACLF) -PhaseⅡclbet365 登録ical trials